Harriet Fear, CEO of not-for-profit One Nucleus, has been appointed a Member of the Order of the British Empire in the Queens Birthday 2016 Honours List. The award recognises her services to the life science sector.
UK biotech Bicycle Therapeutics has established US operations in Cambridge (MA). Rosamund Deegan, appointed to the newly established role of President and Chief Business Officer, will be responsible for leading the companys US business development and for establishing a team in the US.
Manchester University spin-out C4X Discovery Holdings plc has a new CEO. UK biotech notable Clive Dix has taken over the helm of the UK drug discovery company. Dix joined C4XD as Non-Executive Chairman in October 2014 and became Executive Chairman in November 2015.
After replacing several management positions over the last year, Polands leading generics producer Polpharma now also has a new head. Markus Sieger has succeeded Maurice Chagnaud as President of the Management Board and CEO.
Research service provider Envigo has appointed Patricia Henahan as Chief Financial Officer. She has held similar roles at Eli Lilly, AstraZeneca, Medimmune and Hospira.
In early May, Alfredo Zurlo took over the role of Chief Medical Officer at Berlin-based clinical-stage immuno-oncology company Glycotope. He joins from Mologen, where he held the position of CMO, too, and was also a member of the Executive Board.
Dutch gene therapy play uniQure has nominated Jack Kaye to its Board of Directors. Kaye will also chair the uniQures Audit Committee.
RS Genomics, formed to provide broad access to CRISPR/Cas9 IP, has appointed Eric Rhodes as its new CEO. He joins the company from Horizon Discovery where he held the role of Senior Vice President of R&D and Chief Technology Officer.
In early June, the Hungarian National Association of Drugmakers (Magyosz) elected István Hodász as its general chairman. Hodász is CEO and managing director of the Egis Pharmaceuticals Plc, a unit of France’s Servier.
When Sanofi sells its animal health division Merial, CEO Carsten Hellmann will join Danish allergy specialist ALK Albello as the next President and CEO. He will also give up his seat on the Executive Committee and his position of Executive Vice President at Sanofi.